Immatics (IMTX) Interest Expenses (2019 - 2025)
Immatics (IMTX) posted Interest Expenses of $41.0 million for Q4 2025, up 12229.44% sequentially from -$337856.9 in Q3 2025, and up 16629.98% YoY from N/an in Q4 2024.
Immatics (IMTX) Interest Expenses (2019 - 2025) Analysis & Trends
Immatics has reported Interest Expenses for 7 years, with the latest figure at $41.0 million in Q4 2025.
- Quarterly Interest Expenses rose 16629.98% year-over-year to $41.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $52.4 million (up 461.84% YoY) and the FY2025 annual result came in at $41.4 million, up 2997.37% from the prior year.
- Interest Expenses advanced to $41.0 million in Q4 2025 per IMTX's latest filing, from -$337856.9 in the prior quarter.
- Over five years, Interest Expenses peaked at $41.0 million in Q4 2025 and troughed at -$14.0 million in Q1 2025.
- A 5-year average of $1.4 million and a median of -$582495.9 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2025: Interest Expenses slumped 4511.8% in 2021, then jumped 16629.98% in 2025.
- Over 5 years, Interest Expenses stood at -$372934.5 in 2021, then tumbled by 1631.44% to -$6.5 million in 2022, then soared by 220.99% to $7.8 million in 2023, then tumbled by 103.17% to -$247914.1 in 2024, then surged by 16629.98% to $41.0 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $41.0 million, -$337856.9, and $25.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | -42.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 40.98 Mn |
| Dec 31, 2025 | 40.98 Mn |
| Sep 30, 2025 | -337,856.92 |
| Sep 30, 2025 | -337,856.92 |
| Jun 30, 2025 | 25.78 Mn |
| Jun 30, 2025 | 25.78 Mn |
| Mar 31, 2025 | -14.03 Mn |
| Mar 31, 2025 | -14.03 Mn |
| Dec 31, 2024 | -247,914.13 |
| Dec 31, 2024 | -247,914.13 |
| Sep 30, 2024 | -13.83 Mn |
| Sep 30, 2024 | -13.83 Mn |
| Jun 30, 2024 | 328,450.71 |
| Jun 30, 2024 | 328,450.71 |
| Mar 31, 2024 | -735,466.92 |
| Mar 31, 2024 | -735,466.92 |
| Dec 31, 2023 | 7.81 Mn |
| Dec 31, 2023 | 7.81 Mn |
| Sep 30, 2023 | -1.71 Mn |
| Sep 30, 2023 | -1.71 Mn |